My husband has been diagnosed with nsclc stage 4. The cancer has spread to bones in back, pelvic & femur. His doctor tested him for gene therapy & apparently he was in the 16% of people that would benefit from tarceva. Doctor said he had the mutation that tarceva would target. Does anyone know about this?